AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 2 study titled ‘DESTINY-PanTumor02’ to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) for treating selected HER2-expressing tumors. This study aims to determine the clinical activity and risk-benefit profile of T-DXd in various cancer types, highlighting its potential significance in oncology treatment.
Intervention/Treatment: The study tests Trastuzumab Deruxtecan, a drug administered via intravenous infusion, targeting HER2-expressing tumors to assess its effectiveness and safety.
Study Design: This open-label, non-randomized study employs a parallel intervention model. It includes multiple cohorts focusing on different cancer types, with the primary purpose of treatment, and does not involve any masking.
Study Timeline: The study began on August 18, 2020, with the latest update submitted on July 21, 2025. These dates are crucial as they indicate the study’s progression and the timeline for potential results.
Market Implications: The ongoing study could significantly impact AstraZeneca’s stock performance by potentially expanding its oncology portfolio. Positive results may enhance investor sentiment, especially in the competitive cancer treatment market, where innovation is key.
The study is currently recruiting, with further details available on the ClinicalTrials portal.